18.65SEK-1.06%Mkt Cap: 487.38M SEKP/E: —Last update: 2026-06-01
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on C…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap487.38M SEK
Enterprise Value464.96M SEK
Revenue (TTM)10.67M SEK
Gross Profit6.23M SEK
Net Income (TTM)-14.71M SEK
Revenue/Share0.4260 SEK
Last Price18.65 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)21.18
PEG—
EV/EBITDA-32.94
EV/Revenue43.59
P/S46.19
P/B4.90
EPS (TTM)-0.56
EPS (Forward)0.89
52W Range
9.52052% of range27.20
52W High27.20 SEK
52W Low9.520 SEK
Profitability
Gross Margin81.37%
Oper. Margin-58.16%
EBITDA Margin-132.33%
Profit Margin-192.31%
ROE-15.69%
ROA-14.93%
Growth
Revenue Growth93.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.69M SEK
CapEx (TTM)983.00K SEK
FCF Margin-175.35%
FCF Yield-3.84%
Net Debt-27.65M SEK
Net Debt/EBITDA1.96
Balance Sheet
Debt/Equity5.23
Current Ratio6.41
Quick Ratio6.13
Book Value/Sh3.844 SEK
Cash/Share1.259 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)29.00 SEK
Target Range29.00 SEK – 29.00 SEK
# Analysts1
Ownership
Shares Out.26.13M
Float11.30M
Insiders61.15%
Institutions4.58%
Technical
SMA 5016.64 (+12.1%)
SMA 20016.87 (+10.6%)
Beta0.30
S&P 52W Chg27.70%
Avg Vol (30d)15.24K
Avg Vol (10d)12.66K
Technical Indicators
RSI (14)65.7
MACD0.5594
MACD Signal0.5009
MACD Hist.+0.0585
BB Upper19.75 SEK
BB Middle17.38 SEK
BB Lower15.01 SEK
BB Width27.32%
ATR (14)0.8144 SEK
Vol Ratio (20d)0.79x